<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271113</url>
  </required_header>
  <id_info>
    <org_study_id>GMI-1271-102</org_study_id>
    <nct_id>NCT02271113</nct_id>
  </id_info>
  <brief_title>Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Placebo Controlled, Phase1 Study to Assess the Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlycoMimetics Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlycoMimetics Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will evaluate the safety, pharmacokinetics and effect on
      target biomarkers of coagulation, cell adhesion, and leukocyte and platelet activation of
      GMI-1271, an E-selectin antagonist, in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will evaluate in a single ascending dose (SAD) and multiple ascending dose
      (MAD) fashion, the safety, pharmacokinetics and effect on target biomarkers of coagulation,
      cell adhesion, and leukocyte and platelet activation of GMI-1271, an E-selectin antagonist,
      in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events as a measure of safety and tolerability</measure>
    <time_frame>14-19 days</time_frame>
    <description>Adverse Event data review</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of adverse events as a measure of safety and tolerability</measure>
    <time_frame>14-19 days</time_frame>
    <description>Adverse Event data review</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events as a measure of safety and tolerability</measure>
    <time_frame>14-19 days</time_frame>
    <description>Adverse Event data review</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Review of lab results as a measure of Pharmacokinetics</measure>
    <time_frame>3-5 days</time_frame>
    <description>Cmax (mg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Review of lab results as a measure of Pharmacokinetics</measure>
    <time_frame>3-5 days</time_frame>
    <description>AUC (mg/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding</measure>
    <time_frame>14-19 days</time_frame>
    <description>Adverse Event data review</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>GMI-1271</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV GMI-1271</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin Sodium (Lovenox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SC Lovenox®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMI-1271</intervention_name>
    <arm_group_label>GMI-1271</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin Sodium (Lovenox®)</intervention_name>
    <arm_group_label>Enoxaparin Sodium (Lovenox®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  Male or female

          -  Medically healthy, as defined by the absence of clinically significant screening
             results (e.g. laboratory profile, medical history, electrocardiogram (ECG), physical
             examination)

          -  BMI 18-35 kg/m2

          -  Voluntary consent to participate in the study

          -  No evidence of Lower Extremity Deep Vein Thrombosis (LE DVT) at baseline by ultrasound

        Exclusion Criteria:

          -  Use of any prescription, investigational, herbal, supplemental, or over the counter
             medications including aspirin within 14 days (for the SAD phase) and 7 days (for the
             MAD phase) prior to day 1 or unwilling/unable to refrain from the use of these
             medications on days 1-8 for the SAD phase and days 1-12 of the MAD phase of the study

          -  Previous administration of GMI-1271

          -  Positive drug testing at screening and baseline or positive alcohol testing at
             baseline or unwilling/unable to refrain from the use of drugs or alcohol on days 1-8
             for the SAD phase and days 1-12 for the MAD phase of the study

          -  Pregnant or breastfeeding

          -  Unwilling or unable to use contraception during the time of participation in the trial
             and 14 days afterwards (sexual abstinence is permissible)

          -  Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody at screening

          -  Hypersensitivity or allergic reaction to compounds related to GMI-1271

          -  Use of moderate caffeine (≥ 300 mg/day) within 48 hours prior to dosing (day 1)

          -  History of bleeding disorder

          -  Any liver function test &gt; 1.5 times upper limit of normal or renal insufficiency with
             creatinine clearance &lt; 30 ml/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Sood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

